Drug repurposing to new medical uses and chiral switches are elements of secondary pharmaceuticals. This article focuses on drug repurposing/chiral switches of the diastereomeric quasi-enantiomeric antimalarial quinine and antiarrhythmic quinidine, based on the histories of these drugs (1638–2022), applying a widened scope. Quinine, an essential medicine, changed the world. Drug repurposing is a strategy for identifying new uses for approved or investigational drugs outside the scope of the original medical indications. Potential drugs are not included in the definition of drug repurposing. Drug repurposing may be within or outside the therapeutic group, e.g., quinidine to quinine repurposing, from treatment of arrhythmia or severe malaria to uncomplicated malaria. The scope of chiral switches included racemate to single enantiomer and other switches of the status of chirality, e.g., racemate and quasi-racemate to scalemic mixtures. There are 16 quinine/quinidine stereoisomers. Given the multiple pharmacological activities of Cinchona alkaloid stereoisomers, this article calls for subjecting them to comprehensive drug repurposing/chiral switch searches for new medical uses.
{"title":"Widened scope of drug repurposing/chiral switches, elements of secondary pharmaceuticals: the quinine/quinidine case","authors":"Ilaria D’Acquarica, Israel Agranat","doi":"10.4155/fdd-2023-0006","DOIUrl":"https://doi.org/10.4155/fdd-2023-0006","url":null,"abstract":"Drug repurposing to new medical uses and chiral switches are elements of secondary pharmaceuticals. This article focuses on drug repurposing/chiral switches of the diastereomeric quasi-enantiomeric antimalarial quinine and antiarrhythmic quinidine, based on the histories of these drugs (1638–2022), applying a widened scope. Quinine, an essential medicine, changed the world. Drug repurposing is a strategy for identifying new uses for approved or investigational drugs outside the scope of the original medical indications. Potential drugs are not included in the definition of drug repurposing. Drug repurposing may be within or outside the therapeutic group, e.g., quinidine to quinine repurposing, from treatment of arrhythmia or severe malaria to uncomplicated malaria. The scope of chiral switches included racemate to single enantiomer and other switches of the status of chirality, e.g., racemate and quasi-racemate to scalemic mixtures. There are 16 quinine/quinidine stereoisomers. Given the multiple pharmacological activities of Cinchona alkaloid stereoisomers, this article calls for subjecting them to comprehensive drug repurposing/chiral switch searches for new medical uses.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2024-02-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"140448167","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur
Aim: A bacterial genetics-guided approach was utilized for the discovery of new compounds affecting bacterial genome stability. Materials & methods: Fungal extracts and fractions were tested for genome instability-mediated antibacterial activity. Interaction assays and RT-qPCR were used to identify compounds that boost the activity of sub-minimum inhibitory concentration streptomycin and obtain insights on the molecular mechanisms of the primary hit compound, respectively. Results: Several extracts and fractions caused bacterial genome instability. Codeine, in synergy with streptomycin, regulates double-strand break (DSB) repair and causes bacterial ribosome dysfunction in the absence of DSBs, and dysregulation of ribosome biogenesis in a DSB-dependent manner. Conclusion: This study demonstrates a potential viable strategy that we are exploring for the discovery of new chemical entities with activities against Escherichia coli and other bacterial pathogens.
{"title":"Codeine dysregulates ribosome biogenesis in <i>Escherichia coli</i> with DNA double-strand breaks to chart path to new classes of antibiotics","authors":"Vincent Amarh, Benaiah Annertey Abbey, Samuel Akwasi Acheampong, Michael Acheampong Debrah, Gwendolyn Nita Amarquaye, Patrick Kobina Arthur","doi":"10.4155/fdd-2023-0005","DOIUrl":"https://doi.org/10.4155/fdd-2023-0005","url":null,"abstract":"Aim: A bacterial genetics-guided approach was utilized for the discovery of new compounds affecting bacterial genome stability. Materials & methods: Fungal extracts and fractions were tested for genome instability-mediated antibacterial activity. Interaction assays and RT-qPCR were used to identify compounds that boost the activity of sub-minimum inhibitory concentration streptomycin and obtain insights on the molecular mechanisms of the primary hit compound, respectively. Results: Several extracts and fractions caused bacterial genome instability. Codeine, in synergy with streptomycin, regulates double-strand break (DSB) repair and causes bacterial ribosome dysfunction in the absence of DSBs, and dysregulation of ribosome biogenesis in a DSB-dependent manner. Conclusion: This study demonstrates a potential viable strategy that we are exploring for the discovery of new chemical entities with activities against Escherichia coli and other bacterial pathogens.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-10-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136062471","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Aim: The role of peptides is nowadays relevant in fields, such as drug discovery and biotechnology. Computational analyses are required to study their properties and gain insights into rational design strategies. Materials & methods: PepFun 2.0 is a new version of the python package for the study of peptides using a set of modules to analyze the sequence and structure of the molecules. Both natural and modified peptides containing non-natural amino acids can be studied based on the provided functionalities. Results: PepFun 2.0 comprises five main modules for tasks such as sequence alignments, prediction of properties, generation of conformers, detection of interactions and extra functions to include peptides containing non-natural amino acids. Conclusion: The code, tutorial and specific examples are open source and available at: https://github.com/rochoa85/PepFun2 .
{"title":"PepFun 2.0: improved protocols for the analysis of natural and modified peptides","authors":"R. Ochoa","doi":"10.4155/fdd-2023-0004","DOIUrl":"https://doi.org/10.4155/fdd-2023-0004","url":null,"abstract":"Aim: The role of peptides is nowadays relevant in fields, such as drug discovery and biotechnology. Computational analyses are required to study their properties and gain insights into rational design strategies. Materials & methods: PepFun 2.0 is a new version of the python package for the study of peptides using a set of modules to analyze the sequence and structure of the molecules. Both natural and modified peptides containing non-natural amino acids can be studied based on the provided functionalities. Results: PepFun 2.0 comprises five main modules for tasks such as sequence alignments, prediction of properties, generation of conformers, detection of interactions and extra functions to include peptides containing non-natural amino acids. Conclusion: The code, tutorial and specific examples are open source and available at: https://github.com/rochoa85/PepFun2 .","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-08-24","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45896506","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Paulo Ricardo Viviurka do Carmo, Ricardo Marcacini, Marilia Valli, João Victor Silva-Silva, Leonardo Luiz Gomes Ferreira, Alan Cesar Pilon, Vanderlan da Silva Bolzani, Adriano D Andricopulo, Edgard Marx
Aim: This study aimed to develop a chemoinformatic tool for extracting natural product information from academic literature. Materials & methods: Machine learning graph embeddings were used to extract knowledge from a knowledge graph, connecting properties, molecular data and BERTopic topics. Results: Metapath2Vec performed best in extracting compound names and showed improvement over evaluation stages. Embedding Propagation on Heterogeneous Networks achieved the best performance in extracting bioactivity information. Metapath2Vec excelled in extracting species information, while DeepWalk and Node2Vec performed well in one stage for species location extraction. Embedding Propagation on Heterogeneous Networks consistently improved performance and achieved the best overall scores. Unsupervised embeddings effectively extracted knowledge, with different methods excelling in different scenarios. Conclusion: This research establishes a foundation for frameworks in knowledge extraction, benefiting sustainable resource use.
{"title":"Development of a novel chemoinformatic tool for natural product databases","authors":"Paulo Ricardo Viviurka do Carmo, Ricardo Marcacini, Marilia Valli, João Victor Silva-Silva, Leonardo Luiz Gomes Ferreira, Alan Cesar Pilon, Vanderlan da Silva Bolzani, Adriano D Andricopulo, Edgard Marx","doi":"10.4155/fdd-2023-0007","DOIUrl":"https://doi.org/10.4155/fdd-2023-0007","url":null,"abstract":"Aim: This study aimed to develop a chemoinformatic tool for extracting natural product information from academic literature. Materials & methods: Machine learning graph embeddings were used to extract knowledge from a knowledge graph, connecting properties, molecular data and BERTopic topics. Results: Metapath2Vec performed best in extracting compound names and showed improvement over evaluation stages. Embedding Propagation on Heterogeneous Networks achieved the best performance in extracting bioactivity information. Metapath2Vec excelled in extracting species information, while DeepWalk and Node2Vec performed well in one stage for species location extraction. Embedding Propagation on Heterogeneous Networks consistently improved performance and achieved the best overall scores. Unsupervised embeddings effectively extracted knowledge, with different methods excelling in different scenarios. Conclusion: This research establishes a foundation for frameworks in knowledge extraction, benefiting sustainable resource use.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"135143751","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Computational approaches to targeting protein–protein interactions in cancer: a pathway to drug discovery","authors":"M. Okereke, K. David, O. Adedeji","doi":"10.4155/fdd-2023-0003","DOIUrl":"https://doi.org/10.4155/fdd-2023-0003","url":null,"abstract":"","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-05-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"44594827","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Pub Date : 2023-03-01Epub Date: 2023-03-27DOI: 10.4155/fdd-2022-0011
Thuy-Tien T Nguyen, William P Katt, Richard A Cerione
Metabolic reprogramming is a major hallmark of malignant transformation in cancer, and part of the so-called Warburg effect, in which the upregulation of glutamine catabolism plays a major role. The glutaminase enzymes convert glutamine to glutamate, which initiates this pathway. Inhibition of different forms of glutaminase (KGA, GAC, or LGA) demonstrated potential as an emerging anti-cancer therapeutic strategy. The regulation of these enzymes, and the molecular basis for their inhibition, have been the focus of much recent research. This review will explore the recent progress in understanding the molecular basis for activation and inhibition of different forms of glutaminase, as well as the recent focus on combination therapies of glutaminase inhibitors with other anti-cancer drugs.
{"title":"Alone and together: current approaches to targeting glutaminase enzymes as part of anti-cancer therapies.","authors":"Thuy-Tien T Nguyen, William P Katt, Richard A Cerione","doi":"10.4155/fdd-2022-0011","DOIUrl":"10.4155/fdd-2022-0011","url":null,"abstract":"<p><p>Metabolic reprogramming is a major hallmark of malignant transformation in cancer, and part of the so-called Warburg effect, in which the upregulation of glutamine catabolism plays a major role. The glutaminase enzymes convert glutamine to glutamate, which initiates this pathway. Inhibition of different forms of glutaminase (KGA, GAC, or LGA) demonstrated potential as an emerging anti-cancer therapeutic strategy. The regulation of these enzymes, and the molecular basis for their inhibition, have been the focus of much recent research. This review will explore the recent progress in understanding the molecular basis for activation and inhibition of different forms of glutaminase, as well as the recent focus on combination therapies of glutaminase inhibitors with other anti-cancer drugs.</p>","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/2b/98/fdd-04-79.PMC10051075.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10119513","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
P. Back, Kaitlin Rascon, Md. Rakibul Islam, Christopher Selby, N. M. La‐Beck
The immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma by significantly increasing survival rates, with the promise of durable disease remission in some patients. Herein we review the role of immune checkpoints in melanoma; the history of melanoma immunotherapy; pivotal clinical trial data for ipilimumab, pembrolizumab, nivolumab and relatlimab; and the current clinical role of each ICI. We discuss the challenges that accompany these triumphs in the treatment of melanoma, including: how to distinguish between responders and nonresponders; how to optimize ICI dosing and combinatorial approaches; and the best practices for monitoring response and managing immune-related toxicities. We offer our perspective on the financial toxicity of ICIs and new developments that could deliver answers to current challenges.
{"title":"Targeting immune checkpoint pathways in melanoma: triumphs and challenges","authors":"P. Back, Kaitlin Rascon, Md. Rakibul Islam, Christopher Selby, N. M. La‐Beck","doi":"10.4155/fdd-2022-0010","DOIUrl":"https://doi.org/10.4155/fdd-2022-0010","url":null,"abstract":"The immune checkpoint inhibitors (ICIs) have revolutionized the treatment of advanced melanoma by significantly increasing survival rates, with the promise of durable disease remission in some patients. Herein we review the role of immune checkpoints in melanoma; the history of melanoma immunotherapy; pivotal clinical trial data for ipilimumab, pembrolizumab, nivolumab and relatlimab; and the current clinical role of each ICI. We discuss the challenges that accompany these triumphs in the treatment of melanoma, including: how to distinguish between responders and nonresponders; how to optimize ICI dosing and combinatorial approaches; and the best practices for monitoring response and managing immune-related toxicities. We offer our perspective on the financial toxicity of ICIs and new developments that could deliver answers to current challenges.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"43220195","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu
study results suggest that miR-205 / NEU1 can be a viable therapeutic target for treatment of NAFLD. In the series of experiments conducted on mouse models, it was found that miR-205 has an effect on transcription factor ZEBI, which has a role in liver metabolism and insulin resistance [20] . On the other hand, when NZ10 mice were predisposed with obesity, Type 2 diabetes and hepatic steatosis; fed with high protein fish oil diet and examined for the biochemical and physical functions, results showed that the diet prevented steatosis and reduced serum cholesterol and triglycerides
{"title":"miRNA-205: a future therapeutic molecule for liver diseases.","authors":"Marco Cabrera, Meghana Kolli, Meena Jaggi, Subhash C Chauhan, Murali M Yallapu","doi":"10.4155/fdd-2022-0012","DOIUrl":"https://doi.org/10.4155/fdd-2022-0012","url":null,"abstract":"study results suggest that miR-205 / NEU1 can be a viable therapeutic target for treatment of NAFLD. In the series of experiments conducted on mouse models, it was found that miR-205 has an effect on transcription factor ZEBI, which has a role in liver metabolism and insulin resistance [20] . On the other hand, when NZ10 mice were predisposed with obesity, Type 2 diabetes and hepatic steatosis; fed with high protein fish oil diet and examined for the biochemical and physical functions, results showed that the diet prevented steatosis and reduced serum cholesterol and triglycerides","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2023-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/a2/d0/fdd-04-78.PMC9990095.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9101090","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Shedding light on the dark genome: drugging long non-coding RNA","authors":"Stefan Schiesser, Werngard Czechtizky, R. J. Cox","doi":"10.4155/fdd-2022-0009","DOIUrl":"https://doi.org/10.4155/fdd-2022-0009","url":null,"abstract":"","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-15","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42013261","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
Peptides have traditionally been perceived as poor drug candidates due to unfavorable characteristics mainly regarding their pharmacokinetic behavior, including plasma stability, membrane permeability and circulation half-life. Nonetheless, in recent years, general strategies to tackle those shortcomings have been established, and peptides are subsequently gaining increasing interest as drugs due to their unique ability to combine the advantages of antibodies and small molecules. Macrocyclic peptides are a special focus of drug development efforts due to their ability to address so called ‘undruggable’ targets characterized by large and flat protein surfaces lacking binding pockets. Here, the main strategies developed to date for adapting peptides for clinical use are summarized, which may soon help usher in an age highly shaped by peptide-based therapeutics. Nonetheless, limited membrane permeability is still to overcome before peptide therapeutics will be broadly accepted.
{"title":"Overcoming the shortcomings of peptide-based therapeutics","authors":"C. Lamers","doi":"10.4155/fdd-2022-0005","DOIUrl":"https://doi.org/10.4155/fdd-2022-0005","url":null,"abstract":"Peptides have traditionally been perceived as poor drug candidates due to unfavorable characteristics mainly regarding their pharmacokinetic behavior, including plasma stability, membrane permeability and circulation half-life. Nonetheless, in recent years, general strategies to tackle those shortcomings have been established, and peptides are subsequently gaining increasing interest as drugs due to their unique ability to combine the advantages of antibodies and small molecules. Macrocyclic peptides are a special focus of drug development efforts due to their ability to address so called ‘undruggable’ targets characterized by large and flat protein surfaces lacking binding pockets. Here, the main strategies developed to date for adapting peptides for clinical use are summarized, which may soon help usher in an age highly shaped by peptide-based therapeutics. Nonetheless, limited membrane permeability is still to overcome before peptide therapeutics will be broadly accepted.","PeriodicalId":73122,"journal":{"name":"Future drug discovery","volume":null,"pages":null},"PeriodicalIF":0.0,"publicationDate":"2022-07-11","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46169376","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
京公网安备 11010802042870号
京ICP备2023020795号-1
扫码关注我们
求助内容：
应助结果提醒方式：